<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cevimeline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cevimeline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cevimeline: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11700" href="/d/html/11700.html" rel="external">see "Cevimeline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F149142"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Evoxac</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F149160"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cholinergic Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F149146"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="601ee7dc-a5e9-4fd0-be6c-83b4e912db8a">Xerostomia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Xerostomia (associated with Sjögren disease): Oral:</b> 30 mg 3 times/day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989975"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987314"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F149147"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F149118"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (11%), sinusitis (12%), upper respiratory tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1% to 3%), edema (1% to 3%), palpitations (1% to 3%), peripheral edema (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash (1% to 3%), pruritus (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8%), anorexia (1% to 3%), aphthous stomatitis (1% to 3%), constipation (1% to 3%), enlargement of salivary glands (1% to 3%), eructation (1% to 3%), flatulence (1% to 3%), gastroesophageal reflux disease (1% to 3%), hiccups (1% to 3%), increased serum amylase (1% to 3%), salivary gland pain (1% to 3%), sialadenitis (1% to 3%), sialorrhea (2%), vomiting (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (1% to 3%), urinary tract infection (6%), vaginitis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (1% to 3%), fungal infection (1% to 3%), infection (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (1% to 3%), fatigue (3%), hypertonia (1% to 3%), hypoesthesia (1% to 3%), hyporeflexia (1% to 3%), insomnia (2%), migraine (1% to 3%), tremor (1% to 3%), vertigo (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (4%), back pain (5%), lower limb cramp (1% to 3%), myalgia (1% to 3%), skeletal pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye infection (1% to 3%), eye pain (1% to 3%), visual disturbance (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (4%), cough (6%), epistaxis (1% to 3%), flu-like symptoms (1% to 3%), pneumonia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Asthenia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (Petrone 2002), ECG abnormality (Petrone 2002), hypotension (Petrone 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (Petrone 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis, diarrhea (Petrone 2002), dyspepsia (Fife 2002), dysphagia (Petrone 2002), parotid gland enlargement (Noaiseh 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast swelling (Noaiseh 2014), urinary frequency (Fife 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Mouth edema (Petrone 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (Petrone 2002), headache (Petrone 2002), paranoid ideation (Petrone 2002)</p></div>
<div class="block coi drugH1Div" id="F149129"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cevimeline or any component of the formulation; uncontrolled asthma; when miosis is undesirable (eg, narrow-angle glaucoma,  acute iritis)</p></div>
<div class="block war drugH1Div" id="F149115"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Parasympathomimetic effects: Toxicity is characterized by an exaggeration of parasympathomimetic effects (eg, atrioventricular block, bradycardia, cardiac arrhythmia, hypotension, lacrimation, sweating, respiratory distress, tachycardia, tremors, vomiting); excessive sweating may lead to dehydration in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Visual effects: May cause blurred vision, decreased visual acuity (particularly at night and in patients with central lens changes) and impaired depth perception. Patients should be cautioned about driving at night or performing hazardous activities in reduced lighting.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Use with caution in patients with significant cardiovascular disease (including angina, myocardial infarction); may alter cardiac conduction and/or heart rate.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cholelithiasis: Use with caution in patients with a history of cholelithiasis; may induce contractions of the gallbladder or biliary smooth muscle, precipitating complications such as cholangitis, cholecystitis, or biliary obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Nephrolithiasis: Use with caution in patients with a history of nephrolithiasis; may induce smooth muscle spasms, precipitating renal colic or ureteral reflux in patients with nephrolithiasis.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Respiratory disease: Use with caution in patients with controlled asthma, COPD, or chronic bronchitis; may increase bronchial smooth muscle tone, airway resistance, and bronchial secretions.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Patients with CYP2D6 deficiency: Patients with a known or suspected deficiency of CYP2D6 may be at higher risk of adverse effects.</p></div>
<div class="block foc drugH1Div" id="F149125"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evoxac: 30 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg</p></div>
<div class="block geq drugH1Div" id="F149111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F149130"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cevimeline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $3.48 - $3.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Evoxac Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $9.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block use drugH1Div" id="F149126"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Xerostomia (associated with Sjögren disease):</b> Treatment of symptoms of dry mouth in patients with Sjögren disease.</p></div>
<div class="block mst drugH1Div" id="F149167"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cevimeline may be confused with Savella</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evoxac may be confused with Eurax</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F149154"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F149120"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Cholinergic Agonists may enhance the adverse/toxic effect of Rivastigmine. Specifically, cholinergic effects may be enhanced or increased. Rivastigmine may enhance the adverse/toxic effect of Cholinergic Agonists.  Management: Use of rivastigmine with a cholinergic agonist is not recommended unless clinically necessary. If the combination is necessary, monitor for increased cholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F149131"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects were observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F20613499"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if cevimeline is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F149114"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to muscarinic (cholinergic) receptors, causing an increase in secretion of exocrine glands (such as salivary and sweat glands) and increase tone of smooth muscle in gastrointestinal and urinary tracts</p></div>
<div class="block phk drugH1Div" id="F149128"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; food decreases rate of absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 6 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2D6, CYP3A3, and CYP3A4; metabolites: cis and trans-sulfoxide, glucuronic acid conjugate, N-oxide metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5 ± 1 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.5 to 2.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (84% in 24 hours, 97% in 7 days); feces (0.5% in 7 days).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F149133"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Evoxac</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Evoxac | Saligren</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Evoxac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Evoxac</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Evoxac</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Evoxac (cevimeline) [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12038948">
<a name="12038948"></a>Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. <i>Arch Intern Med</i>. 2002;162(11):1293-1300. doi:10.1001/archinte.162.11.1293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cevimeline-drug-information/abstract-text/12038948/pubmed" id="12038948" target="_blank">12038948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25065774">
<a name="25065774"></a>Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome. <i>Clin Exp Rheumatol</i>. 2014;32(4):575-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cevimeline-drug-information/abstract-text/25065774/pubmed" id="25065774" target="_blank">25065774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11920411">
<a name="11920411"></a>Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. <i>Arthritis Rheum</i>. 2002;46(3):748-754. doi:10.1002/art.510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cevimeline-drug-information/abstract-text/11920411/pubmed" id="11920411" target="_blank">11920411</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8884 Version 200.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
